evekhm/cms_iom_500 huggingface dataset:
(Medicare National Coverage Determinations Manual)
Photodynamic Therapy CIM 35-100 80.3 Photosensitive Drugs CIM 45-30 80.4 Hydrophilic Contact Lenses CIM 65-1 80.5 Scleral Shell CIM 65.3 80.6 Intraocular Photography CIM 35-39 80.7 Refractive Keratoplasty CIM 35-54 80.8 Endothelial Cell Photography   CIM 50-38 80.9 Computer Enhanced Perimetry CIM 50-49 80.10 Phaco-Emulsification Procedure  (Cataract Extraction) CIM 35-9 80.11 Vitrectomy CIM 35-16 80.12 Intraocular Lenses (IOLs) CIM 65-7 90 Genetics Reserved - no text 100 Gastrointestinal System Header 100.1 Gastric Bypass Surgery for Obesity CIM 35-40 100.2 Endoscopy CIM 35-59 100.3 24-Hour Ambulatory Esophegeal pH Monitoring CIM 35-83 100.4 Esophageal Manometry CIM 50-25 100.5 Diagnostic Breath Analyses CIM 50-51 NCD Section Title CIM Section # 100.6 Gastric Freezing CIM 35-65 100.7 Colonic Irrigation CIM 35-1 100.8 Intestinal By-Pass Surgery CIM 35-33 100.9 Implantation of Anti-Gastroesophageal Reflux Device CIM 35-69 100.10 Injection Sclerotherapy for Esophageal Variceal Bleeding   CIM 35-73 100.11 Gastric Balloon for Treatment of Obesity CIM 35-86 100.12 Gastrophotography CIM 50-9 100.13 Laproscopic Cholecystectomy CIM 35-91 110 Hematology/Immunology/Oncology Header 110.1 Hyperthermia for Treatment of Cancer CIM 35-49 110.2 Certain Drugs Distributed by the National Cancer Institute CIM 45-16 110.3 Anti-Inhibitor Coagulant Complex (AICC) CIM 45-24 110.4 Extracorporeal Photopheresis CIM 35-88 110.5 Granulocyte Transfusions CIM 45-18 110.6 Scalp Hypothermia During Chemotherapy to Prevent Hair Loss CIM 45-21 110.7 Blood Transfusions CIM 45-27 110.8 Blood
(Medicare National Coverage Determinations Manual)
Granulocyte Transfusions CIM 45-18 110.6 Scalp Hypothermia During Chemotherapy to Prevent Hair Loss CIM 45-21 110.7 Blood Transfusions CIM 45-27 110.8 Blood Platelet Transfusions CIM 35-30 10.8.1 Stem Cell Transplantation CIM 35.30.1 110.9 Antigens Prepared for Sublingual Administration CIM 45-28 110.10 Intravenous Iron Therapy CIM 45-29 110.11 Food Allergy Testing and Treatment CIM 50-53 NCD Section Title CIM Section # 110.12 Challenge Ingestion Food Testing CIM 50-22 110.13 Cytotoxic Food Tests CIM 50-2 110.14 Apheresis  (Therapeutic Pheresis) CIM 35-60 110.15 Ultrafiltration, Hemoperfusion and Hemofiltration CIM 35-38 110.16 Nonselective (Random) Transfusions and Living Related Donor Specific Transfusions (DST) in Kidney Transplantation CIM 35-71 120 Infectious Diseases Reserved - no text 130 Mental Health Header 130.1 Inpatient Hospital Stays for the Treatment of Alcoholism CIM 35-22 130.2 Outpatient Hospital Services for Treatment of Alcoholism CIM 35-22 130.3 Chemical Aversion Therapy for Treatment of Alcoholism CIM 35-23 130.4 Electrical Aversion Therapy for Treatment of Alcoholism CIM 35-23.1 130.5 Treatment of Alcoholism and Drug Abuse in a Freestanding Clinic CIM 35-22.3 130.6 Treatment of Drug Abuse (Chemical Dependency) CIM 35-22.2 130.7 Withdrawal Treatments for Narcotic Addictions CIM 35-42 130.8 Hemodialysis for Treatment of Schizophrenia CIM 35-51 140 Miscellaneous Surgical Procedures Header 140.1 Abortion  CIM 35-99 140.2 Breast Reconstruction Following Mastectomy CIM 35-47 NCD Section Title CIM Section # 140.3 Transsexual Surgery CIM 35-61 140.4 Plastic Surgery to Correct "Moon Face" CIM 35-12 140.5 Laser Procedures CIM 35-52 150 Musculoskeletal  System Header 150.1 Manipulation CIM 35-2 150.2 Osteogenic Stimulator CIM 35-48 150.3 Bone (Mineral) Density Studies CIM 50-44 150.4
(Medicare National Coverage Determinations Manual)
150 Musculoskeletal  System Header 150.1 Manipulation CIM 35-2 150.2 Osteogenic Stimulator CIM 35-48 150.3 Bone (Mineral) Density Studies CIM 50-44 150.4 Neuromuscular Electrical Stimulator (NMES) in the Treatment of Disuse Atrophy CIM 35-77 150.5 Diathermy Treatment CIM 35-41 150.6 Vitamin B12 Injections to Strengthen Tendons; Ligaments; etc; of the Foot CIM 45-4 150.7 Prolotherapy; Joint Sclerotherapy, and Ligamentous Injections with Sclerosing Agents CIM 35-13 150.8 Fluidized Therapy Dry Heat for Certain Musculoskeletal Disorders CIM 35-56 160 Nervous System Header 160.1 Induced Lesions of Nerve Tracts CIM 35-17 160.2 Treatment of Motor Function Disorders with Electric Nerve Stimulation CIM 35-20 160.3 Assessing Patients Suitability for Electrical Nerve Stimulation CIM 35-46 160.4 Steroetactic Cingulotomy as a Means of Psychosurgery CIM 35-84 160.5 Sterotaxic Depth Electrode Implantation CIM 50-40 160.6 Carotid Sinus Nerve Stimulator CIM 65-4 NCD Section Title CIM Section # 160.7 Electrical Nerve Stimulators CIM 65-8 160.7.1 Assessing Patients Suitability for Electrical Nerve Stimulation Therapy CIM 35-46 160.8 Electroencephalographic Monitoring During Surgical Procedures Involving the Cerebral Vasculature CIM 35-57 160.9 Electroencephalographic (EEG) Monitoring During Open-Heart Surgery CIM 35-57.1 160.10 Evoked Response Tests CIM 50-31 160.11 Osteogenic Stimulation  CIM 35-48 160.12 Neuromuscular Electrical Stimulation (NMES) in the Treatment of Disuse Atrophy CIM 35-77 160.13 Supplies Used in the Delivery of Transcutaneous Electrical Nerve Stimulation (TENS) and Neuromuscular Electrical Stimulation (NMES) CIM 45-25 160.14 Invasive Intracranial Pressure Monitoring CIM 35-62 160.15 Electrotherapy for Treatment of Facial Nerve Palsy (Bells Palsy) CIM 35-72 160.16 Vertebral Axial
(Medicare National Coverage Determinations Manual)
45-25 160.14 Invasive Intracranial Pressure Monitoring CIM 35-62 160.15 Electrotherapy for Treatment of Facial Nerve Palsy (Bells Palsy) CIM 35-72 160.16 Vertebral Axial Decompression (VAX-D) CIM 35-97 160.17 L-Dopa  CIM 45-1 160.18 Vagus Nerve Stimulation for Treatment of Seizures CIM 60-22 160.19 Phrenic Nerve Stimulator CIM 65-13 160.20 Transfer Factor For Treatment of Multiple Sclerosis CIM 45-17 160.21 Telephone Transmission of EEGs CIM 50-39 160.22 Ambulatory EEG Monitoring CIM 50-39.1 160.23 Current Perception Threshold/Sensory Nerve Cond ction Threshold Test(sNCT)CIM - 50-57.1 NCD Section Title CIM Section # Conduction Threshold Test (sNCT) 160.24 Deep Brain Stimulation for Essential Tremor and Parkinsons Disease CIM 65-19 160.25 Multiple Electroconvulsive Therapy (MECT) CIM 35-103 170 Nonphysician Practitioner Services (PT/OT/SLP/Audiologists/CRNA Header 170.1 Institutional and Home Care Patient Education Programs  CIM 80-1 170.2 Melodic Intonation Therapy CIM 35-67 170.3 Speech Pathology Services for the Treatment of Dysphagia CIM 35-89 180 Nutrition Header 180.1 Medical Nutrition Therapy CIM 80-3 180.2 Enteral and Parenteral Nutritional Therapy CIM 65-10 190 Pathology and Laboratory Header 190.1 Histocompatibility Testing CIM 50-23 190.2 Diagnostic Pap Smears CIM 50-20 190.3 Cytogenetic Studies CIM 50-29 190.4 Electron Microscope CIM 50-18 190.5 Sweat Test CIM 50-35 190.6 Hair Analysis CIM 50-24 190.7 Human Tumor Stem Cell Drug Sensitivity Assays CIM 50-41 190.8 Lymphocyte Mitogen Response Assays CIM 50-45 190.9 Serologic Testing for Acquired Immunodeficiency Syndrome (AIDS)  CIM 50-52 NCD Section Title CIM Section # 190.10 Laboratory Tests CRD Patients 190.11   Home Prothrombin Time INR Monitoring for Anticoagulation Management CIM
(Medicare National Coverage Determinations Manual)
Immunodeficiency Syndrome (AIDS)  CIM 50-52 NCD Section Title CIM Section # 190.10 Laboratory Tests CRD Patients 190.11   Home Prothrombin Time INR Monitoring for Anticoagulation Management CIM 50-56 200 Pharmacology Reserved-no text 210 Prevention Header 210.1 Prostate Cancer Screening Tests CIM 50-55 210.2 Screening Pap Smears and Pelvic Examinations for Early Detection of Cervical or Vaginal Cance CIM 50-20.1 220 Radiology Header 220.1 Computerized Tomography  CIM 50-12 220.2 Magnetic Resonance Imaging CIM 50-13  220.3 Magnetic Resonance Angiography CIM 50-14 220.4 Mammograms CIM 50-21 220.5 Ultrasound Diagnostic Procedures CIM 50-7 220.6 Positron Emission Tomography (PET) Scans CIM 50-36 220.7 Xenon Scan CIM 50-27 220.8 Nuclear Radiology Procedure CIM 50-30 220.9 Digital Subtraction Angiography CIM 50-43 220.10 Portable Hand-Held X-Ray Instrument CIM 50-48 220.11 Thermography CIM 50-5 220.12 Single Photon Emission Computed Tomograph  (SPECT) CIM 50-58 220.13 Percutaneous Image-Guided Breast Biopsy CIM 50-59 230 Renal and Genitourinary System, ESRD Services Header 230.1 Treatment of Kidney Stones CIM 35-81 NCD Section Title CIM Section # 230.2 Uroflowmetric Evaluations CIM 35-33 230.3 Sterilization CIM 35-11 230.4 Diagnosis and Treatment of Impotence CIM 35-24 230.5 Gravlee Jet Washer CIM 50-4 230.6 Vabra Aspirator CIM 50-10 230.7 Water Purification and Softening Systems Used in Conjunction with Home Dialysis CIM 55-1 230.8 Non-Implantable Pelvic Flood Electrical Stimulator CIM 60-24 230.9 Cryosurgery of Prostate CIM 35-96 230.10 Incontinence Control Devices CIM 65-9 230.11 Diagnostic Pap Smears CIM 50-20 230.12 Dimethyl Sulfoxide (DMSO)   CIM 45-23 230.13 Peridex CAPD Filter Set
(Medicare National Coverage Determinations Manual)
Control Devices CIM 65-9 230.11 Diagnostic Pap Smears CIM 50-20 230.12 Dimethyl Sulfoxide (DMSO)   CIM 45-23 230.13 Peridex CAPD Filter Set CIM 55-2 230.14 Ultrafiltration Monitor   CIM 55-3 230.15 Electrical Continence Aid CIM 65-2 230.16 Bladder Stimulators (Pacemakers) CIM 65-11 230.17 Urinary Drainage Bags CIM 65-17 230.18 Sacral Nerve Stimulation for Urinary Incontinence CIM 65-18 230.19 Levocarnitine for Use in the Treatment of Carnitine Deficiency in ESRD Patients CIM 45-32 240 Respiratory System Header 240.1 Lung Volume Reduction Surgery (Reduction Pneumoplasty) CIM 35-93 NCD Section Title CIM Section # 240.2 Home Use of Oxygen CIM 60-4 240.3 Heat Treatment, Including the Use of Diathermy and Ultra-Sound for Pulmonary Conditions CIM 35-3 240.4 Continuous Positive Airway Pressure (CPAP) CIM 60-17 240.5 Intrapulmonary Percussive Ventilator (IPV) CIM 60-21 240.6 Transvenous (Catheter) Pulmonary Embolectomy CIM 35-55 240.7 Postural Drainage Procedures and Pulmonary Exercises CIM 35-15 250 Skin Header 250.1 Treatment of Psoriasis CIM 35-66 250.2 Hemorheograph CIM 50-16 250.3 Intravenous Immune Globulin For The Treatment Of Autoimmune Mucutaneous Blistering Diseases  CIM 45-31 250.4 Treatment of Actinic Keratosis CIM 25-101 260 Transplantation - Solid Organ Transplants, Stem Cell Transplantation Header 260.1 Adult Liver Transplantation CIM 35-53 260.2 Pediatric Liver Transplantation CIM 35-53.1 260.3 Pancreas Transplants CIM 35-82 260.4 Lung Transplantation To be added 260.5 Intestinal and Multivisceral Transplantation CIM 35-104 260.6 Dental Examination Prior to Kidney Transplantation CIM 50-26 260.7 Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine)
(Medicare National Coverage Determinations Manual)
CIM 35-104 260.6 Dental Examination Prior to Kidney Transplantation CIM 50-26 260.7 Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine) CIM 45-22 NCD Section Title CIM Section # 260.8 Reserved  260.9 Heart Transplants CIM 35-87 270 Wound Treatment Header 270.1 Electrostimulation in the Treatment of Wounds CIM 35-98 270.2 Noncontact Normothermic Wound Therapy (NNWT) CIM 60-25 270.3 Platelet-Derived Wound Healing Formula CIM 45-26 270.4 Treatment Of Decubitus Ulcers CIM 35-31  270.5 Porcine Skin and Gradient Pressure Dressings CIM 45-12 280 Medical and Surgical Supplies  Header 280.1 Durable Medical Equipment Reference List CIM 60-9 280.2 White Cane for Use by a Blind Person CIM 60-3 280.3 Specially Sized Wheelchairs CIM 60-6 280.4 Seat Lift CIM 60-8 280.5 Safety Roller CIM 60-15 280.6 Pneumatic Compression Devices CIM 60-16 280.7 Hospital Beds CIM 60-18 280.8 Air-Fluidized Bed CIM 60-19 280.9 Power Operated Vehicles That May Be Used as Wheelchairs CIM 60-5 280.10 Prosthetic Shoe CIM 70-3 280.11 Corset Used as Hernia Support CIM 70-1 280.12 Sykes Hernia Control CIM 70-2 280.13 Transcutaneous Electrical Nerve Stimulators (TENS) CIM 60-20 NCD Section Title CIM Section # 280.14 Infusion Pumps CIM 60-14 290 Nursing Services Header 290.1 Home Health Visits to a Blind Diabetic CIM 90-1 290.2 Home Health Nurses' Visits to Patients Requiring Heparin Injections CIM 90-2 300 Diagnostic Tests Not Otherwise Classified Header 300.1 Obsolete or Unreliable Diagnostic Tests CIM 50-34 310  Clinical Trials Header 310.1 Routine Costs in Clinical Trails CIM 30-1
(Medicare National Coverage Determinations Manual)
Medicare National Coverage Determinations Manual  Chapter 1, Part 3 (Sections 170  190.34) Coverage Determinations   Table of Contents  (Rev. 12112, Issued;  06-29-23)  Transmittals for Chapter  1, Part 3
(Medicare National Coverage Determinations Manual)
170 - Nonphysician Practitioner Services (PT/OT/SLP/Audiologists/CRNA ) 170.1 - Institutional and Home Care Patient Education Programs  170.2 - Melodic Intonation Therapy  170.3 - Speech -Language Pathology Services for the Treatment of Dysphagia  180 - Nutrition  180.1 - Medical Nutrition Therapy  (MNT)  180.2 - Enteral and Parenteral Nutritional Therapy  (RETIRED)  190 - Pathology and Laboratory  190.1 - Histocompatibility Testing  190.2 - Diagnostic Pap Smears  190.3 - Cytogenetic Studies  190.4 - Electron Microscope  (RETIRED)  190.5 - Sweat Test  190.6 - Hair Analysis  190.7 - Human Tumor Stem Cell Drug Sensitivity Assays  190.8 - Lymphocyte Mitogen Response Assays  190.9 - Serologic Testing for Acquired Immunodeficiency Syndrome (AIDS)  190.10 - Laboratory Tests - CRD Patients  190.11 - Home Prothrombin Time/International Normalized Ratio (PT/INR) Monitoring for Anticoagulation Management  (Effective March 19, 2008)  190.12 - Urine Culture, Bacterial  190.13 - Human Immunodeficiency Virus (HIV) Testing (Prognosis Including Monitoring)  190.14 - Human Immunodeficiency Virus (HIV) Testing (Diagnosis)  190.15 - Blood Counts  190.16 - Partial Thromboplastin Time (PTT)  190.17 -  Prothrombin Time (PT)  190.18 -  Serum Iron Studies  190.19 -  Collag en Crosslinks, Any Method 190.20 -  Blood Glucose Testing 190.21 -  Glycated Hemoglobin/Glycated Protein  190.22 -  Thyroid Testing 190.23 -  Lipid Testing  190.24 -  Digoxin Therapeutic Drug Assay  190.25 -  Alpha -fetoprotein 190.26 -  Carcinoembryonic Antigen 190.27 -  Human Chorionic Gonadotropin  190.28 -  Tumor Antigen by Immunoassay  CA 125 190.29 -  Tumor Antigen by Immunoassay CA 15- 3/CA 27.29 190.30 -  Tumor Antigen by Immunoass ay CA 19- 9 190.31 -  Prostate Specific Antigen  190.32 -  Gamma Glutamyl Transferase  190.33 -  Hepatitis Panel/Acute Hepatitis Panel 190.34 -  Fecal
(Medicare National Coverage Determinations Manual)
-  Tumor Antigen by Immunoass ay CA 19- 9 190.31 -  Prostate Specific Antigen  190.32 -  Gamma Glutamyl Transferase  190.33 -  Hepatitis Panel/Acute Hepatitis Panel 190.34 -  Fecal Occult Blood Test  170 - Nonphysician Practitioner Services (PT/OT/SLP/Audiologists/CRNA (Rev. 1, 10- 03-03)
(Medicare National Coverage Determinations Manual)
170.1 - Institutional and Home Care Patient Education Programs  (Rev. 1, 10- 03-03) CIM 80 -1  While the Act does not specifically identify patient education programs as covered services, reimbursement may be made under Medicare for such programs furnished by providers of services (i.e., hospitals, SNFs, HHAs, and OPT providers) to the extent that the programs are appropriate, integral parts in the rendition of covered services which are reasonable and necessary for the treatment of the individuals illness or injury.  For example, educational activities carried out by nurses such as teaching patients to give themselves injections, follow prescribed diets, administer colostomy care, administer medical gases, and carry out other inpatient care activities may be reimbursable as a part of covered routine nursing care.  Also, the teaching by an occupational therapist of compensatory techniques to improve a patients level of independence in the a ctivities of daily living may be reimbursed as a part of covered occupational therapy.  Similarly, the instruction of a patient in the carrying out of a maintenance program designed for him/her by a physical therapist may be reimbursed as part of covered physical therapy.  However, when the educational activities are not closely related to the care and treatment of the patient, such as programs directed toward instructing patients or the public generally in preventive health care activities, reimbursement cannot be made since the Act limits Medicare payment to covered care which is reasonable and necessary for the treatment of an illness or injury.  For example, programs designed to prevent illness by instructing the general public in the importance of good nutritional habits, exercise regimens, and good hygiene are not reimbursable under Medicare.   170.2 - Melodic Intonation Therapy (Rev. 1, 10- 03-03) CIM 35 -67  Melodic intonation therapy is a technique used in language rehabilitation.  Its purpose is to teach aphasic patients to produce useful phrases by intoning them in a melodic pattern with strong rhythmic support.  Limited studies by a few institutions show s ome benefit for a small number of nonfluent aphasic patients otherwise unresponsive to conventional therapy.
(Medicare National Coverage Determinations Manual)
Melodic intonation therapy is a covered service only for nonfluent aphasic patients unresponsive to conventional therapy, and only when the condit ions for coverage of speech pathology services are met.  Please refer to the Medicare Benefit Policy, Chapter 15, Covered Medical and Other Health Services, 220; the Medicare Claims Processing Manual, Chapter 5, Part B Outpatient Rehabilitation and COR F Services, for these conditions of coverage.   170.3 - Speech -Language  Pathology Services for the Treatment of Dysphagia (Rev. 55, Issued: 05-05- 06, Effective: 10 -01-06, Implementation: 10-02-06)  Dysphagia is a swallowing disorder that may be due to various neurological, structural, and cognitive deficits.  Dysphagia may be the result of head trauma, cerebrovascular accident, neuromuscular degenerative diseases, head and neck cancer, or encephalopathies.  While dysphagia can afflict any age group, it most often appears among the elderly.  Speech- language pathology services are covered under Medicare for the treatment of dysphagia, regardless of the presence of a communication disability.  Patients who are motivated, moderately alert, and have some degree of deglutition and swallowing functions are appropriate candidates for dysphagia therapy.  Elements of the therapy program can include thermal stimulation to heighten the sensitivity of the swallowing reflex, exercises to improve oral-motor control, training in laryngeal adduction and compensatory swallowing techniques, and positioning and dietary modifications.  Design all programs to ensure swallowing safety of the patient during oral feedings and maintain adequate nutrition.  Cross -reference:   The Medicare Benefit Policy, Chapter 15, Covered Medical and Other Health Services, 220 and 230.3.  180 - Nutrition  (Rev. 1, 10-03-03)  180.1 - Medical Nutrition  Therapy  (MNT)  (Rev. 11426; Issued: 05-20- 22; Effective: 01 -01-22; Implementation: 07 -05-22)  A. General
(Medicare National Coverage Determinations Manual)
A. General   Section 1861(s)(2)(V) of the Social Security Act  authorizes Medicare part B coverage of medical  nutrition therapy services (MNT)  for certain beneficiaries who have diabetes or  a renal  disease.  Regulations for MNT  were  established  on January 2, 2002, at 42 CFR 410.130 - 410.134.  This national coverage determination (NCD) establishes the duration and frequency limits for  the MNT  benefit  and coordinates MNT  and diabetes outpatient self- management training (DSMT)  as an NCD.   B. Nationally Covered   Effective  January 1, 2022, basic coverage of MNT,  for the first  year a beneficiary receives MNT, with either  a diagnosis of renal disease or diabetes as defined at  42 CFR 410.130  is three hours of administration.  Basic coverage in subsequent years for renal disease or diabetes is two hours. The dietitian/nutritionist may  choose how many units are administered per  day as long as all of  the other requirements  in this NCD and 42 CFR 410.130-410.134 are met.  Pursuant to the exception at 42 4CFR 410.132(b)(5), additional hours are considered to be medically necessary  and covered if the physician  determines that there  is a change in medical condition, diagnosis, or treatment regimen that requires a  change in MNT  and orders additional hours during that episode of care.   If the physician determines that receipt  of both MNT and DSMT is medically  necessary  in the same episode of care, Medicare will cover  both DSMT and MNT initial and subsequent years without decreasing either benefit as long as DSMT  and MNT are not provided on the same date of service.  The dietitian/nutritionist may  choose how many  units are performed per day  as long as all of the other requirements in the NCD  and 42 CFR 410.130-410.134  are met.  Pursuant to the exception at 42 CFR 410.132(b)(5), additional hours are considered  to be medically necessary  and covered if the physician determines that there  is a change in medical condition, diagnosis, or treatment regimen that requires a  change in MNT  and orders additional hours during that episode of care.   C. Nationally Non- Covered   N/A  D. Other   N/A  (This NCD last reviewed December 2021.)
(Medicare National Coverage Determinations Manual)
C. Nationally Non- Covered   N/A  D. Other   N/A  (This NCD last reviewed December 2021.)    180.2 - Enteral and Parenteral Nutritional Therapy  (RETIRED)  (Rev. 11892; Issued: 03-09- 23; Effective: 04 -10-23; Implementation:04 -10-23)   Effective January 1, 2022, the Centers for Medicare & Medicaid Services determined  that no national coverage determination (NCD) is appropriate at this time for Enteral  and Parenteral  Nutritional Therapy. In the absence  of an NCD, coverage determinations  will be made by the Medicare Administrative Contractors under 1862(a)(1)(A) of the  Social Security Act.   190 - Pathology and Laboratory  (Rev. 1, 10-03-03)  190.1 - Histocompatibility Testing  (Rev.  12112; Issued: 06-29- 23; Effective: 07 - 31-23; Implementation: 07-31- 23)   Histocompatibility testing involves the matching or typing of the human leucocyte  antigen (HLA). This testing is safe and effective when it is performed on patients:   A.  In preparation for a ki dney transplant;         B .  In preparation for bone marrow transplantation;   C.  In preparation for blood platelet transfusions (particularly where multiple              infusions are involved; or         D .  Who are suspected of having ankylosing spondyliti s.     This testing is covered under Medicare when used for any of the indications listed in A, B, and C  and if it is reasonable and necessary for the patient.   It is covered for ankylosing spondylitis in cases where other methods of diagnosis would not be  appropriate or have yielded inconclusive results. Request documentation supporting the medical necessity of the test from the physician in all cases where ankylosing spondylitis  is indicated as the reason for the test.    190.2 - Diagnostic Pap Smears  (Rev. 48, Issued:  03- 17-06; Effective/Implementation Dates:  06 -19-06) CIM 50 -20, CIM 50 -20.1  A diagnostic pap smear and related medically necessary services are covered under Medicare Part B when ordered by a physician under one of the following conditions:    Previous 4cancer of the cervix, uterus, or vagina that has been or is presently being treated;